Meeting Report
Cancer Gene Therapy (2007) 14, 128–138. doi:10.1038/sj.cgt.7700996; published online 13 October 2006
International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China
B A Guinn1, J S Norris2, F Farzaneh1 and A B Deisseroth3
- 1King's College London School of Medicine, Department of Haematological Medicine, The Rayne Institute, London, UK
- 2Department of Microbiology and Immunology, BSB Medical University of South Carolina, Charleston, SC, USA
- 3Sidney Kimmel Cancer Center, 10835 Road to the Cure, San Diego, CA, USA
Correspondence: Dr BA Guinn, Department of Haematological Medicine, King's College London School of Medicine, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK. E-mail: barbara.guinn@kcl.ac.uk
Received 21 March 2006; Revised 31 July 2006; Accepted 19 August 2006; Published online 13 October 2006.
Abstract
The 2005 International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress was held in Shenzhen, China (www.iscgtchina2005.com) from December 9th–11th 2005. Here, we describe a representation of the most seminal presentations providing an overview of the progress in the field of cancer gene therapy including the successful introduction of the first approved gene therapy drug.
Keywords:
gene therapy, immunotherapy, cancer research, meeting report, International Society for Cell and Gene Therapy of Cancer
Abbreviations:
AC, acid ceramidase; BBB, blood brain barrier; CD, cytosine deaminase; CD40L, CD40 ligand; CTL, cytotoxic T lymphocyte; DC, dendritic cell; ESGT, European Society for Gene Therapy; ES-SCLC, extensive stage – small cell lung carcinoma; FasL, Fas ligand; HCC, hepatocellular cancer; HNSCC, head and neck small cell carcinoma; HSV, herpes simplex virus; i.p., intraperitoneal; ISCGT, International Society for Cell and Gene Therapy of Cancer; i.v., intravenous; LN, lymph node; LTR, long terminal repeat; MK, Midkine; MLV, murine leukemia virus; MMTV, mouse mammary tumor virus; NK, natural killer; NPC, nasopharyngeal carcinoma; RCR, replication-competent retrovirus; RSV, Rous Sarcoma Virus; s.c., subcutaneous; TAA, tumor associated antigen; TACE, transcatheter hepatic arterial; TILs, tumor infiltrating lymphocytes; Tregs, regulatory/suppressor T cells; v.p., viral particle; VSV, vesicular stomatitis virus
